Cholesterol regulates the signaling of µ-opioid receptor in cell models, but has not been demonstrated in mice or humans. In addition, whether cholesterol regulates the signaling by mechanism other than supporting the entirety of lipid raft microdomains is still unknown. By modulating cholesterol-enriched lipid raft microdomains and/or total cellular cholesterol contents in human embryonic kidney cells stably expressing µ-opioid receptor, it is concluded that cholesterol stabilized opioid signaling both by supporting the lipid raft's entirety and by facilitating G protein coupling. Similar phenomena were observed in the primary rat hippocampal neurons. In addition, reducing the brain cholesterol level with simvastatin impaired the analgesia effect of opioids in mice, whereas opioid analgesic effect was enhanced in mice fed with high-cholesterol diet.
4 cellular content of cholesterol and subsequently disrupt the cholesterol-rich lipid raft microdomains. D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (DPDMP), a glucosylceramide synthase inhibitor, blocks the synthesis of glycospingolipids that are also important components of lipid raft microdomains (12) . Thus DPDMP should disrupt lipid raft microdomains without affecting cholesterol content. By monitoring the effects of these two inhibitors on receptor signaling, how cholesterol modulates receptor signaling could be explored partially.
As a typical Gi/o coupled receptor, µ-opioid receptor (OPRM1) locates in the lipid raft microdomains (13) . Reducing cholesterol level not only disrupts the lipid raft microdomains but also attenuates the downstream signaling. Thus OPRM1 is a suitable model to study the mechanisms used by cholesterol to regulate receptor signaling.
Similar to other GPCRs, OPRM1 also exhibits agonist-biased signaling (14) .
Cholesterol has different influences on the signaling induced by these two types of agonists (13) . Extracting the cholesterol attenuates the AC inhibition induced by either morphine or etorphine. Reducing the cholesterol level only inhibits morphine-but not etorphine-induced ERK phosphorylation. To avoid the possible influences from agonistbiased signaling, AC inhibition but not ERK phosphorylation was monitored in the current studies.
In addition, the relationship between cholesterol level and opioid signaling was also tested in the primary cultures of rat hippocampal neurons that have OPRM1 expressed endogenously (15) . Correlation between cholesterol level and in vivo opioid functions was also tested by manipulating the cholesterol level in mice and by analyzing the clinic records of patients. 
Results

Simvastatin and DPDMP modulate membrane composition
Human embryonic kidney (HEK) cells stably expressing OPRM1, which were named HEKOPRM1, was used in the current study. These cells have OPRM1 expressed exogenously at about 6 pmol/mg protein. To decrease the cholesterol level in the HEKOPRM1 cells, simvastatin, a HMG-CoA reductase inhibitor, was used. As indicated in Fig. 1A , 12-hour treatment with 0.5 µM simvastatin induced a 43±13% (n=4) decrease in cholesterol level on cell membrane and a 68±11% (n=4) decrease in whole cell lysate.
These decreases were not due to the DMSO which was used to dissolve the simvastatin (stock concentration of simvastatin: 1 mM) (Fig. 1A) . In addition, when the cells were cultured in medium supplemented with 40 ng/ml cholesterol for 12 hrs, the cholesterol levels were increased. When both simvastatin and cholesterol were included in the culture medium, no significant change on cholesterol level was observed (Fig. 1A) .
DPDMP was used to inhibit glucosylceramide synthase and to block the synthesis of glycospingolipids. The effect of DPDMP was verified by using Cholera toxin B conjugated with FITC (CTX-B-FITC) to stain the monosialotetrahexosylganglioside (GM1) on cell membrane. As indicated in Fig. 1B , 12-hour treatment with 20 µM DPDMP decreased membrane GM1 to 47±12% (n=4) of the basal level. But simvastatin and cholesterol did not affect the amount of membrane GM1 (Fig. 1B) . DPDMP treatment had no effect on the cellular cholesterol levels (Fig. 1A) .
Both simvastatin and DPDMP disrupt lipid raft microdomains
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Continuous sucrose gradient was used to separate the purified cell membrane of HEKOPRM1 cells into twelve fractions, and the cholesterol levels in first ten fractions were then determined. More cholesterol was identified in fractions 4 and 5 than in other fractions ( Fig. 2A) . To quantify this enrichment, the cholesterol amount in fraction 6 was compared with that in fraction 4, the ratio is 0.54±0.04 and 0.56±0.07 (n=4) in control and DMSO-treated cells, respectively (Fig. 2B) . 12-hour simvastatin treatment disrupted this enrichment of cholesterol and increased the ratio to 1.10±0.09, n=4 (Fig. 2B) .
Cholesterol antagonized the effect of simvastatin and rescued the ratio to the basal level, when was added to the medium at the same time with simvastatin. Therefore, modulating cholesterol level with simvastatin affects the organization of cell membrane by inhibiting cholesterol synthesis.
Although DPDMP treatment did not alter the total cholesterol level either in whole cell homogenates or in cell membrane preparations (Fig 1A) , DPDMP treatment disrupted the lipid raft microdomains in HEKOPRM1 cells as reported with other cell lines (16) (17) (18) ). The ratio of cholesterol level in fraction 6 to that in fraction 4 was increased to 1.04±0.11, n=4 (Fig. 2B) . Thus inhibiting glucosylceramide synthase with DPDMP also affects the organization of cell membrane.
In order to compare the functions of simvastatin and DPDMP, the dose-dependency of the two inhibitors to affect cholesterol enrichment were determined ( Fig. 2C and 2D ). 0.5 μM simvastatin and 20 μM DPDMP induced similar and close to maximum impairment on cholesterol enrichment. These concentrations of simvastatin and DPDMP were used in subsequent studies to investigate the probable mechanism of cholesterol effects on OPRM1 signaling. If simvastatin and DPDMP both disrupted the lipid raft microdomains, consistent membrane distributions of Gαi2 (marker of lipid raft microdomains) and transferrin receptor (TR, marker of non-raft microdomains) should be observed after these treatments (19) . In control untreated HEKOPRM1 cells, the ratio of Gαi2 amount in faction 6 to that in fraction 4 was 0.35±0.03 (n=4). This ratio was increased to 5.52±0.55 and 5.10±0.47 (n=4) after treatment with simvastatin and DPDMP, respectively (Fig. 3A) .
Cholesterol treatment decreased this ratio to 0.20±0.03 when used alone, and rescued the ratio to basal level (0.38±0.07, n=4) when used with simvastatin (Fig. 3A) . The distribution of TR was not affected by these treatments, since majority of TR locates in the non-raft microdomains (Fig. 3B ). As many other GPCRs (1, 13), OPRM1 locates within the lipid raft in the absence of agonist (Fig. 3C) . To further verify the entirety of lipid raft, the amounts of receptor in fraction 6 were compared with those in faction 4. In control and DMSO-treated cells, OPRM1 located in the lipid raft microdomains (Fig. 3D ).
OPRM1 translocated into non-raft microdomains after treatment with either simvastatin or DPDMP. Thus both simvastatin and DPDMP treatment disrupted the lipid raft microdomains.
Simvastatin and DPDMP treatments alter OPRM1 signaling differentially
Decreasing cholesterol level leads to the attenuation of morphine-induced signaling in HEKOPRM1 cells (13) . The intracellular level of cAMP was monitored to determine how cholesterol affects the abilities of opioids to induce AC inhibition. Morphine induced AC inhibition with a K I value of 11.5±2.0 nM and a maxmium inhibition at 85±3.1% (n=4) in control untreated cells (Table I) . AC inhibition was attenuated in by guest, on October 30, 2017 www.jlr.org Downloaded from simvastatin-treated HEKOPRM1 cells. This attenuation could be prevented when 40 ng/ml cholesterol was included in the medium. DPDMP treatment also decreased the ability of morphine to induce AC inhibition.
When the effects of simvastatin on morphine-induced AC inhibition were compared with those of DPDMP, significant differences were identified (Table I ). Simvastatin impaired the maximal AC inhibition by about 49%, whereas DPDMP impaired this only by about 27%. Since simvastatin and DPDMP disrupted lipid raft microdomains similarly and near totally at these concentrations ( Fig. 2C and D) , the difference in modulating receptor signaling should be due to their different abilities to affect cholesterol content thereby leading to lipid raft disruption.
When fentanyl was used as the agonist, similar observations were obtained (Table   I ). Simvastatin had higher ability than DPDMP to impair fentanyl-induced AC inhibition.
Thus, cellular cholesterol content probably affects receptor signaling by mechanism other than supporting the entirety of lipid raft microdomains.
Dual functions of cholesterol in regulating receptor signaling
Simvastatin, but not DPDMP, decreased the cellular content of cholesterol (Fig. 1 ).
In addition, the two inhibitors exhibited differences in their abilities to affect opioidinduced AC inhibition. Thus cholesterol might contribute to receptor signaling via two mechanisms: supporting the entirety of lipid raft microdomains and facilitating receptor signaling directly. The higher ability of simvastatin to impair receptor signaling than DPDMP could be due to the ability of simvastatin to impair both mechanisms. Opioid-induced AC inhibition has been suggested to be mediated by Gαi2, and OPRM1 is anchored to the lipid raft microdomain by Gαi2 in the absence of agonist (13) .
Thus cholesterol may regulate receptor signaling by influencing receptor-G protein coupling directly.
Receptor-Gαi2 coupling was determined by testing the fluorescence resonance energy transfer (FRET) between CFPOPRM1 and YFPGαi2 in HEK cells. The amounts of transfected CFPOPRM1 and YFPGαi2 was tightly controlled to achieve similar expression levels of fluorescence conjugated proteins in different experimental groups.
As indicated in Fig. 4 , the normalized net FRET value under control condition was 0.38±0.03 (n=12), which could be decreased to 0.20±0.06 (n=12) by 0.5 µM simvastatin.
The dose-dependency of simvastatin to affect receptor-G protein coupling was also determined. However, DPDMP did not affect Gαi2 coupling as indicated by the normalized net FRET value after this inhibitor treatment (0.39±0.05, n=12, Fig. 4A ).
In summary, DPDMP disrupted lipid raft microdomains, but did not affect Gαi2 coupling with the receptor. Thus lipid raft microdomains contribute to receptor signaling by mechanism other than protein partitioning into the microdomains thereby facilitating receptor-G protein coupling due to their proximity. In addition, the higher ability of simvastatin than DPDMP to impair AC inhibition could be explained by the fact that simvastatin not only disrupted lipid raft microdomains but also decreased the cholesterol content. Thus cholesterol contributes to receptor signaling both by supporting the entirety of lipid raft microdomains, but also by stabilizing the interaction between receptor and Gαi2 directly. 
Dual functions of cholesterol in primary neuronal cultures
The HEKOPRM1 cell used above heterologously expressed high level of OPRM1.
In order to establish similar cholesterol effect on endogenously expressed OPRM1, the AC inhibition was also monitored in the primary cultures of rat hippocampal neurons.
The AC inhibition induced by opioids was much lower in primary cultures of rat hippocampal neurons than in HEKOPRM1 cells. Morphine induced AC inhibition with K I and maximum inhibition at 20.3±2.3 nM and 35±2.9% (n=4), respectively (Table II) .
The ability of morphine to induce AC inhibition in primary cultures was only about 41% of that in HEKOPRM1 cells. However, similar results were observed with the two inhibitors.
Simvastatin attenuated opioid-induced AC inhibition more significantly (maximum inhibition from 35±2.9% to 14±2.7%, n=4) than did DPDMP (maximum inhibition from 35±2.9% to 22±2.6%, n=4). Thus the dual functions of cholesterol in regulating receptor signaling also exist in endogenously expressed OPRM1.
Simvastatin decreases the antinociceptive effects of opioids in mice
Cholesterol content influenced the signaling of OPRM1 in both HEKOPRM1 cells and primary neuron cultures. Whether cholesterol can affect the in vivo functions of opioids remains to be demonstrated. We decided to lower the in vivo cholesterol level in mice by the injection of simvastatin. Two-month old CD-1 mice were divided into two groups. One group of mice was injected with 10mg/kg simvastatin subcutaneously three times a day for fourteen days. The other group of mice was given vehicle with the same schedule. The mice injected with vehicle gained weight quicker (10±2%, n=32) than the mice injected with simvastatin (2±2%, n=32) (Fig. 5A ). However, there was no significant difference between the amounts of food/ water consumed.
Fourteen-day injection of simvastatin decreased the serum cholesterol from 114±16 mg/dl (n=64) to 67±9 mg/dl (n=32) (Fig. 5B ). In addition, the cholesterol contents in different regions of mice brains were also determined. Although brain cholesterol level is tightly regulated (20) , statins including simvastatin and lovastatin can modulate the brain cholesterol level (21, 22) . The cholesterol contents in cortex, cerebellum, hippocampus and periaqueductal gray (PAG) in mice injected with simvastatin were decreased. It has been reported that OPRM1 has high expression level in hippocampus and PAG (23) The antinociceptive effects of opioids were measured both before and after the simvastatin or vehicle administration. On Day 0, the ED50 value of morphine was determined to be 2.7 (1.9~3.9) mg/kg (Table III) . When morphine antinociceptive effect was tested in the mice injected with simvastatin for fourteen days, a right ward shift of the dose response curve was observed and the morphine ED50 value increased to 5.6 (4.2~9.1) mg/kg. The decrease in morphine ED50 was not due to the change in the baseline of tail flick response (Table III) .
The antinociceptive effect of fentanyl was also determined under the same paradigm, 14-day simvastatin treatment increased the ED50 value of fentanyl from 27 (20~35) µg/kg to 50 (36~79) µg/kg (Table III) . Thus, similar to morphine, the antinociceptive effect of fentanyl can be influenced by serum, brain, and membrane cholesterol level.
High-cholesterol diet increases the antinociceptive effect of opioids
To further test the correlation between cholesterol content and opioid antinociceptive effect in mice, special designed diet from Testdiet (Richmond, IN) was given to the mice.
The control diet (58R4) was not supplemented with cholesterol, and only 10.3% of the whole energy (3.78kcal/g) was provided by the fat. The high-cholesterol diet (5S8M) was supplemented with 5% cholesterol by weight, and 42.9% of the whole energy (4.63kcal/g) was provided by fat. The detailed ingredients of the two diets were listed in Table IV. Two-month old CD-1 mice were divided into two groups. One group of mice was fed with control diet for 48 days. The other group of mice was fed with high-cholesterol diet.
The mice fed with control diet gained weight by 37±2%, whereas the weight of the mice fed with high-cholesterol diet increased by 59±2% after 48 days (n=32 Fig. 6A ).
However, there was no significant difference in the food or water consumption.
High-cholesterol diet increased the serum cholesterol from 115±17 mg/dl (n=64) to 278±33 mg/dl (n=32), whereas control diet did not influence the serum cholesterol level significantly (Fig. 6B) . The cholesterol contents in cortex, cerebellum, hippocampus, and PAG were increased by 51±18%, 56±21, 53±20%, and 52±21% respectively. As indicated in Fig. 6C , there was a 28±17% increase in the membrane cholesterol in hippocampal region, and a 22±15% increase in PAG region. Thus the high cholesterol diet efficiently increases the cholesterol level in mouse brain.
When morphine antinociceptive effect was tested in the mice fed with highcholesterol diet for 48 days, a left ward shift of the dose response curve was observed and the ED50 value decreased to 1.6 (1.2~2.1) mg/kg. Similar observations were obtained when fentanyl was used. Therefore cholesterol level does affect the opioid agonist antinociceptive effects (Table III) .
Cholesterol level correlates with the fentanyl usage in human subjects
An analysis of the clinic records in China-Japan Friendship Hospital (Beijing, China) was carried out so as to determine whether a relationship exists between serum cholesterol level and opioid functions in humans.
151 clinical records of patients received orthopaedic surgery were selected from more than two thousands of orthopaedic surgery records. These patients received either the decompression of thoracic canal (with the fusion of bone graft and the pedicle screw fixation) or the bilateral total hip arthroplasty. These patients had serum cholesterol level recorded before the surgery. These patients did not have severe diseases or received intensive treatment for the last five years. Since these patients were administered with fentanyl to achieve the similar level of general endotracheal anesthesia at the beginning of surgery, the amounts of fentanyl were used to reflect the efficacy of fentanyl in these patients.
As indicated in the Fig. 7A and B, these 151 patients were separated into two groups according to their gender, and their total serum cholesterol levels (mmol/L) were plotted against the fentanyl amounts used before the surgery (μg/kg). The correlation between cholesterol levels and fentanyl usage was tested with two-tailed Pearson rank test (parametric). In male patients the Pearson's rank correlation coefficient was -0.3864 with p value at 0.0006 (Gaussian approximation, n=75) (Fig. 7A) . In female patients the Pearson's rank correlation coefficient was -0.4371 with p value less than 0.0001 (Gaussian approximation, n=76) (Fig. 7B) .
The two males and the two females with the highest cholesterol levels were then removed from our analysis to exclude any possible influence from these extreme cases. In male patients the Pearson's rank correlation coefficient was -0.3517 with p value at 0.0023 (Gaussian approximation, n=73). In female patients the Pearson's rank correlation coefficient was -0.3998 with p value at 0.0004 (Gaussian approximation, n=74). In addition, we also tested the correlation between cholesterol levels and fentanyl usages in patients whose serum cholesterol levels were between 3.2 and 6.2 mmol/L. In male patients the Pearson's rank correlation coefficient was -0.3062 with p value at 0.0117 (Gaussian approximation, n=67). In female patients the Pearson's rank correlation coefficient was -0.2722 with p value at 0.0258 (Gaussian approximation, n=67).
In addition, no correlation between body mass index (BMI) and cholesterol level was identified in the current study. The p values of Pearson test were 0.5444 (n=75) in male patients and 0.3769 (n=76) in female patients (Fig. 7C and D) . In addition there was no correlation between BMI and fentanyl level. The p values of Pearson test were 0.3966 (n=75) in male patients and 0.0785 (n=76) in female patients (Fig. 7E and F) .
We then selected patient pairs in the clinic records to carry out further analysis. The two patients in one pair had similar ages (the age difference was less than 5 years) and similar BMI (the smaller BMI was more than 90% of the larger BMI), but significant difference in serum cholesterol (cholesterol difference was larger than 2mmol/L). Only fentanyl used by the patients with higher serum cholesterol level was at least 30% less than that used by the patient with lower serum cholesterol.
Therefore, a negative correlation between the serum cholesterol level and opioid efficacy exists in human subjects as observed with in vitro cell models and in vivo antinociceptive response in mice. Since cholesterol contributes to the signaling of many other GPCRs by maintaining the entirety of lipid raft microdomains (1), it is reasonable to deduce that lowering cholesterol may also impair the functions of other GPCRs. Since over 40% marketed drugs are targeting GPCRs, thus lowering the cholesterol to a level under normal may impair the efficacies of these drugs.
In order for the opioids to function, they must cross the blood-brain barrier. Hence, subjects with larger fat tissues should have reduced but sustained opioid effects. Since the study was carried out to correlate cholesterol level and the usage of fentanyl at the beginning of surgery, subjects with higher cholesterol level or larger fat tissues should use more fentanyl to achieve the similar anesthesia stage if the pharmacokinetic was the major determinant. However, the actual observation was just the opposite, which suggested that the pharmacokinetics or the drug distribution was not the critical determinant under current paradigm.
Opioid function is more sensitive to the decrease than to the increase of cellular cholesterol level
Because the blood-brain barrier is impermeable to circulating lipoprotein-bound cholesterol, it is considered difficult to modulate the cholesterol level in central nervous system under normal conditions. However, we managed to control the brain cholesterol content in the current studies similar to other reports (21, 22, 28) . As predicted, the modulations on serum cholesterol were much greater than those on brain regions (Fig. 5   and 6 ). The extreme conditions of high doses of simvastatin (10 mg/kg per injection, three injections per day for 14 days) and elevated cholesterol in the diet (5% in diet, and about 43% energy from fat) might be the reason why we were able to control brain cholesterol level successfully. Although these high doses of simvastatin and cholesterol would not be used in clinic under normal conditions, they enabled us to investigate the possible consequences when brain cholesterol level was modulated and might have clinic implications when patients with abnormal cholesterol level were considered.
The signaling capability of OPRM1 was more sensitive to the decrease than to the increase in cholesterol content. On the one hand, high-cholesterol diet increased the cholesterol content on the membrane from PAG by 22±15%, whereas decreased the ED50 value only by about 45%. On the other hand, simvastatin administration decreased the cholesterol content by 19±10%, but increased the ED50 value of morphine by about 107 %. Similar phenomena were observed with the HEKOPRM1 cells.
These phenomena suggested that the cholesterol content on the cell membrane under normal condition was sufficient to support the function of OPRM1. Thus the increase in cholesterol content may be difficult to enhance the signaling of receptor, since the receptor level is the limiting factor. In addition, it was also reasonable to suggest the influence on drug efficacy might not be observed when the cholesterol level could not be increased by a large amount in vivo.
The dual functions of cholesterol in regulating receptor signaling
Cholesterol-lowering chemicals disrupt lipid raft microdomains and subsequently affect OPRM1 signaling. This observation has been explained by that lipid raft microdomains provide the environment for the signaling molecules to interact with receptor (29). In the current studies, we demonstrated that maintaining lipid raft microdomains is not the only mechanism in which cholesterol controls receptor signaling.
The concentrations of the two inhibitors that could disrupt lipid rafts were titrated so as to achieve the similar effects on lipid raft microdomains. However, the two inhibitors exhibited differential effects when the AC inhibition and G-protein coupling were monitored. Since, the effects induced by simvastatin could be restored by cholesterol supplement and only simvastatin reduced cellular cholesterol level, it is suggested that cholesterol could regulate receptor signaling via mechanism other than maintaining lipid raft microdomains.
Since simvastatin but not DPDMP affect the receptor-Gαi2 coupling, the lipid raft integrity should not contribute to the receptor-Gαi2 coupling. Thus the decreased receptor-Gαi2 coupling after simvastatin treatment might be due to the reduction in cholesterol content within the receptor signaling complex. Based on these observations we concluded that cholesterol regulate OPRM1 signaling via two mechanisms: 1) facilitating the receptor-Gαi2 coupling; 2) maintaining the entirety of lipid raft microdomains, which might provide the environment for the interaction between receptor and signaling molecules.
Although cholesterol did not selectively affect AC inhibition and analgesia effects induced by different opioids, the possible influence of interaction between cholesterol and agonist-biased signaling could not be eliminated.
In summary, the current studies demonstrated the mechanisms used by cholesterol to regulated OPRM1 signaling in HEKOPRM1 cells. The correlation between cholesterol content and opioid function was illustrated both in vitro (HEKOPRM1 cells and primary cultures) and in vivo (mice and humans). These results not only extend the understanding on GPCR signaling, but also provide valuable information on the probable clinical interactions between opioids and cholesterol lowering drugs.
Materials and Methods
Cell models and OPRM1 signaling
HEK293 cells which stably express OPRM1 and primary cultures of rat hippocampal neurons were prepared as described previously (15, 30) . Opioid-induced AC inhibition was quantified by measuring the intracellular cAMP level according to the previous reports (31). The data was analyzed by using GraphPad Prism 5.0.
Animal Studies
The For simvastatin experiment, one group of mice was given simvastatin subcutaneously at 10mg/kg, three times a day for 14 days. Another group was given vehicle in the same paradigm. For cholesterol supplement experiment, one group of mice was fed with control diet (58R4), while another group was fed with high-cholesterol diet (5S8M) for 48 days. The information of the diet was listed in Table SII. The ED50 values of opioids were measured before and after the diet manipulations. The doses of simvastatin and cholesterol were much higher than those under normal conditions. These high doses were used to modulate brain cholesterol level and to access the possible consequences.
Continuous sucrose gradient
Cells or tissues were homogenized in 0.32 M sucrose and 10 mM HEPES (pH 7.7).
Crude lysate was then centrifuged at 1,000g for 10 minutes at 4°C, the supernatant was collected and the pellet was re-homogenized. These processes were repeated until the pellet appeared translucent. The collected supernatant was centrifuged at 100,000g for 60 minutes at 4°C. The resulted pellet was dissolved in 0.5 M sodium carbonate and then under-laid in a 5-30% continuous sucrose gradient generated with the Gradient Station (BioComp, Fredericton, Canada) and centrifuged for 16-hour at 32,00 rpm in a SW41 rotor (Beckman, Brea, CA) as reported previously (13) . The gradient was then separated into 12 fractions (1ml each from low to high density). Cholesterol concentrations were determined in the first ten fractions using an Amplex Red Cholesterol Assay Kit (Invitrogen, Carlsbad, CA). The amount of OPRM1 in the same fractions was determined by using [ 3 H] diprenorphine binding as described previously (32).
Membrane Purification and Cholesterol Assay
Cholesterol concentrations were determined by using the Amplex Red Cholesterol Assay Kit (Invitrogen, Carlsbad, CA) on the cell membrane preparation and whole cell lysate. 
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Human Studies
The human studies in current report did not include any analysis of human samples. All the studies were based on the patients' clinical records. The investigation was conducted according to Declaration of Helsinki principles and approved by the Institutional Review Board. The written informed consents were received from participants or their representatives prior to inclusion in the study. Participants were identified by number, not by name.
Transient Transfection
The pCMV-shuttle vector (Stratagene) was used in current studies. Data were analyzed by one-way ANOVA with Dunnett-test as post-hoc test. The error bars and "*" represented the standard deviation (n>=4) and significant difference from "Control", respectively. There were also significant differences between "simvastatin" and "DPDMP" groups. Table 2 Cholesterol level affects opioids signaling in primary hippocampal cultures
The primary neuron cultures were treated with PBS (Control), DMSO (DMSO), 0.5 μM simvastatin (Simvastatin), 0.5 μM simvastatin with 40ng/ml cholesterol (Simva+Chol), 40ng/ml cholesterol (Cholesterol) or 20 M DPDMP for 24 hours. AC inhibition was carried out and analyzed as in Table 1 . There were also significant differences between "simvastatin" and "DPDMP" groups. Table 4 Ingredients of control and high-cholesterol diets
The ingredients of the control diet (58R4) and high cholesterol diet (5S8M) were listed.
The energy provided by the different compositions of the diets was also listed. www.jlr.org
